These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18723490)

  • 21. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Liu Q; Mier JW; Panka DJ
    Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
    Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
    Dickens MP; Roxburgh P; Hock A; Mezna M; Kellam B; Vousden KH; Fischer PM
    Bioorg Med Chem; 2013 Nov; 21(22):6868-77. PubMed ID: 24113239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.
    Ding Y; Lee JF; Lu H; Lee MH; Yan DH
    Mol Cell Biol; 2006 Mar; 26(5):1979-96. PubMed ID: 16479015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
    Linares LK; Scheffner M
    FEBS Lett; 2003 Nov; 554(1-2):73-6. PubMed ID: 14596917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
    Moumen A; Masterson P; O'Connor MJ; Jackson SP
    Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2.
    Linares LK; Kiernan R; Triboulet R; Chable-Bessia C; Latreille D; Cuvier O; Lacroix M; Le Cam L; Coux O; Benkirane M
    Nat Cell Biol; 2007 Mar; 9(3):331-8. PubMed ID: 17293853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.
    Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L
    J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitination.
    Bhatt P; d'Avout C; Kane NS; Borowiec JA; Saxena A
    FEBS J; 2012 Feb; 279(3):370-83. PubMed ID: 22103682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
    D'Arcy P; Maruwge W; Ryan BA; Brodin B
    Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
    Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
    Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
    Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
    J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress.
    Bai D; Zhang J; Xiao W; Zheng X
    Nucleic Acids Res; 2014 Feb; 42(3):1799-811. PubMed ID: 24174547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.
    Obata M; Kominami R; Mishima Y
    Cell Signal; 2012 May; 24(5):1047-52. PubMed ID: 22245141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions.
    Hara T; Durell SR; Myers MC; Appella DH
    J Am Chem Soc; 2006 Feb; 128(6):1995-2004. PubMed ID: 16464101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.